<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00507390</url>
  </required_header>
  <id_info>
    <org_study_id>200306ver2</org_study_id>
    <nct_id>NCT00507390</nct_id>
  </id_info>
  <brief_title>Omega 3 Polyunsaturated Fatty Acid Supplements (PUFAs) and Microvolt T Wave Alternans (TWA) in Patients With Ventricular Arrhythmia</brief_title>
  <official_title>The Effect of Omega-3 Polyunsaturated Fatty Acid Supplements on Microvolt T Wave Alternans in Patients With Ventricular Arrhythmia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a hypothesis testing study, the hypothesis being that dietary supplements of n-PUFAs
      concentrates are anti-arrhythmic in ventricular arrhythmic substrates.

      Study Aims: To investigate whether dietary supplements of n-3 polyunsaturated fatty acid
      concentrates (2g PUFAs/day, Omacor) reduces MTWA (a surrogate endpoint for ventricular
      arrhythmia substrate) in patients with ICDs for malignant ventricular arrhythmias.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients from the Department of Cardiology ICD out-patient clinic, Ninewells Hospital and
      Medical School, will be recruited. All these patients have a history of documented
      ventricular arrhythmia. Data from previous studies predict that 90% of these patients will
      have abnormal MTWA. A total of 45 ICD patients will be recruited. The study design will be a
      double blind randomised placebo controlled crossover design. A baseline MTWA test will be
      performed and patients with an abnormal test will be selected. The patients will be
      randomised to receive fish oil supplements (2g/day) or placebo for 8 weeks each. At the end
      of each intervention period, a repeat MWTA test will be performed. A 10 ml venous blood
      sampled will also be collected at baseline, and after each intervention period (3 samples in
      total). Patients in atrial fibrillation, frequent atrial or ventricular ectopics, or with
      ventricular pacing from the ICD, unstable angina, NYHA IV heart failure, pregnancy or child
      bearing potential will be excluded from the study.

      End Points of the Study. The primary endpoint will be quantitative and qualitative measures
      of MTWA during n-3 PUFAs treatment compared to placebo.

      Statistical Analysis: Quantitative differences in MTWA measurements will be analysed by a
      Student's t-test and qualitative differences by a chi squared test. A probability of 0.05%
      will be considered significant.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    funding not secured
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in microvolt T wave alternans status</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Arrhythmia</condition>
  <condition>Defibrillators, Implantable</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>n-3 PUFAs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>olive oil capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>n-3 polyunsaturated fatty acids (PUFAs)</intervention_name>
    <description>2g n-3 PUFAs once daily for 8 weeks</description>
    <arm_group_label>A1</arm_group_label>
    <other_name>Omacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>olive oil</intervention_name>
    <description>1 capsule day</description>
    <arm_group_label>A2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  implantable cardiovertor defibrillators

          -  microvolt Twave alternans positive

        Exclusion Criteria:

          -  unstable angina

          -  CHF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan Struthers, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ninewells Hospital and medical School</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2007</study_first_submitted>
  <study_first_submitted_qc>July 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2007</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Dundee</investigator_affiliation>
    <investigator_full_name>AChoy</investigator_full_name>
    <investigator_title>Senior Clinical Lecturer and Honorary Consultant Cardiologist</investigator_title>
  </responsible_party>
  <keyword>fish oils</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

